Navigation Links
ThromboGenics NV Announces Business Update and Half Year Results 2009

success fee.

    Corporate Update

    - As of 1 July 2009, ThromboGenics was promoted to the NEXT 150
      index on the Euronext stock exchange, reflecting the strong share price
      performance and progress that the Company has made. The NEXT 150 index
      comprises mid to large capitalization stocks on the Euronext exchange.
      The index consists of the 150 next largest stocks following the
      Euronext 100 index and includes stocks from the Amsterdam, Brussels,
      Lisbon and Paris exchanges of Euronext.

      The inclusion of the Company in the NEXT 150 index also
      follows the Company entering the VLAM-21 index earlier in the year,
      which is a capitalized-weighted index of the 21 most capitalized
      Flemish stocks that are traded on a stock exchange.

    - Cross-border merger of ThromboGenics NV and ThromboGenics Ltd
      finalized, leading to a streamlined legal structure and cost savings.

    - ThromboGenics has continued to strengthen its in-house
      expertise, following the strategic hires announced at the time of the
      Company's first quarter 2009 Business Update. In June, Dr. Clive Long
      joined ThromboGenics as Head of Pre-Clinical Program Management. Dr.
      Long joins from Schering-Plough, where he was Proof-of-Concept Leader
      and has 26 years experience working for large pharmaceutical companies
      in research and development.

    Financial Overview
    Revenue and Results

In the first half of 2009, ThromboGenics achieved total revenue of EUR3.6 million, nearly all of which came from its out-licensing activities. Within this amount, EUR3 million came from the first success fee from Roche based on the successful transfer and implementation of technology and process development for TB-403 production. In the same period of 2008, ThromboGenics had revenues of EUR30.3 million due to the upfront payment from Roche which resulted from the signi

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ThromboGenics NV: Business Update
2. ThromboGenics Announces Business Update and 2008 Full Year Results
3. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
4. ThromboGenics N.V.: Business Update
5. ThromboGenics Announces Half Year Results 2008
6. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
7. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
8. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
9. ThromboGenics N.V. - Business Update
10. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
11. ThromboGenics Announces 2007 Full Year Results
Post Your Comments:
(Date:8/27/2014)... 2014 Tris Pharma, a specialty pharmaceutical company ... that it has been selected as an award winner ... 2014 Awards for Excellence competition in the Business ... of judges from SCORE (Counselors to America,s Small Business) ... honored at a gala event to be held on ...
(Date:8/27/2014)... City, OR (PRWEB) August 27, 2014 ... stands to reason that the next beverage craze is ... Technology announced today that formulators can use Stress Relief ... ingredient used in the making of a beverage, including ... release for stress-generated energy, channeling that power into rapid ...
(Date:8/27/2014)... Cranford, NJ (PRWEB) August 27, 2014 ... and services – has once again shown superiority when ... trial sponsor by completing the ePRO portion of their ... results. The Japan-based pharma chose WriteResult’s digital writing ... IBS trials – the first to complete drew data ...
(Date:8/26/2014)... LOS ANGELES , Aug. 26, 2014  NeuroSigma, ... sciences company established to develop bioelectronic technologies, today announced ... S-1 with the U.S. Securities and Exchange Commission relating ... stock. The number of shares to be offered and ... yet been determined. Jefferies LLC will act ...
Breaking Biology Technology:Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 4A Perfect Record: WriteResult Maintains a 100% On-Time ePRO Record with Latest Irritable Bowel (IBS) Study Data Lock 2
... Colo., Sept. 24 InVitria,( ) ... "Optimizing Cell Culture Development" Conference on,September 15-16 ... recent,results optimizing cell culture media using its ... ), In a presentation of ...
... use of AHCC for immune enhancement during cold & ... new paper published in,Nutrition Reviews (Vol. 66(9):526-531) by Dr. ... Drexel University, has shown,how AHCC impacts the immune response ... review analyzed outcomes from in vivo studies evaluating,the effect ...
... Calif., Sept. 24 NeurogesX, Inc.,(Nasdaq: NGSX ... novel pain management therapies, announced today that it,has ... (EMEA) Day 120,questions to support the Marketing Authorization ... NeurogesX, MAA for NGX-4010 in peripheral neuropathic pain ...
Cached Biology Technology:InVitria Touts Product Advantages at Cambridge's Cell Culture Conference 2Research Shows How AHCC(R) May Help Fight Flu and Other Infectious Agents 2NeurogesX Responds to EMEA's Day 120 Questions 2NeurogesX Responds to EMEA's Day 120 Questions 3
(Date:8/27/2014)... 400 million years ago a group of fish began exploring ... and mammals. But just how these ancient fish used their ... evolutionary processes were at play remain scientific mysteries. , ... , turned to a living fish, called Polypterus , ... attempted to walk out of the water. Polypterus ...
(Date:8/27/2014)... brain of mice, scientists have altered the emotional ... Howard Hughes Medical Institute investigator Susumu Tonegawa at ... the connections between the part of the brain ... the part of the brain that stores the ... , Altering those connections can transform a negative ...
(Date:8/27/2014)... greatest risk to Europe based upon a proxy for ... using a ,big data, approach to scientific research. , ... Global Health ranked the top 100 pathogens affecting humans ... system which, they believe, will help governments across the ... infectious diseases, including as a result of climate change, ...
Breaking Biology News(10 mins):Walking fish reveal how our ancestors evolved onto land 2Researchers change the emotional association of memories 2Researchers change the emotional association of memories 3Researchers change the emotional association of memories 4Big data approach identifies Europe's most dangerous human and domestic animal pathogens 2
... 12, 2009) HOBOKEN, NJ According to the ... U.S. population will have hemorrhoids by the age of ... hemorrhoids is over-the-counter remedies, most patients do not report ... they are in severe distress, including bleeding. A ...
... A growing number of scientists are merging methods and results ... says a team of researchers in a recent issue of ... focused on new data, however, researchers who want to analyze ... institutional support, the authors say. In a commentary piece in ...
... - Mango. If you know little about this fruit, understand ... and breast cancer cells in the lab. That,s ... scientists, who examined the five varieties most common in the ... the mango is an ancient fruit heavily consumed in many ...
Cached Biology News:Study shows pine bark naturally relieves symptoms of acute hemorrhoids 2Study shows pine bark naturally relieves symptoms of acute hemorrhoids 3Biologists merge methods, results from different disciplines to find new meaning in old data 2Biologists merge methods, results from different disciplines to find new meaning in old data 3Mango effective in preventing, stopping certain colon, breast cancer cells 2
... number is a new ... easily match Cornings product ... availability yet, please order ... number (Z35,347-7) or contact ...
... Freedom EVO384R are fast multi-channel pipetting platforms ... different sizes, with a multi-channel head and ... time saving, with true parallel processing of ... your assays with the Freedom EVOware program. ...
... EVO384R are fast multi-channel pipetting platforms consisting ... sizes, with a multi-channel head and a ... saving, with true parallel processing of sample ... assays with the Freedom EVOware program. ...
Prepared by multi-temperature ethanol fractionation with extensive charcoal treatment and dialysis.• Assay: ≥ 95 % (HPCE)• pH ~5.2 (10 mg/mL in 0.15 M NaCl)...
Biology Products: